Neervannan Seshadri 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 19, 2024
Insider Transaction Report
Form 4
Neervannan Seshadri
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2024-03-15+13,245→ 69,646 total - Sale
Common Stock
2024-03-18$30.60/sh−4,879$149,297→ 64,767 total - Exercise/Conversion
Restricted Stock Units
2024-03-15−5,097→ 10,194 total→ Common Stock (5,097 underlying) - Exercise/Conversion
Restricted Stock Units
2024-03-15−8,148→ 24,444 total→ Common Stock (8,148 underlying)
Footnotes (6)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
- [F2]Includes 1,705 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023.
- [F3]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F4]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F5]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
- [F6]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.